1 Alzheimer Europe Report (2020): Dementia in Europe Yearbook 2019. Estimating the prevalence of dementia in Europe.
3 Bundesamt für Gesundheit (BAG). Zahlen & Fakten zu Demenz – Prävalenzschätzungen zu Demenzerkrankungen in der Schweiz. Abrufbar unter
https://www.bag.admin.ch/bag/de/home/zahlen-und-statistiken/zahlen-fakten-demenz.html.
4 Ecoplan (Kraft E, Iseli S). Alzheimer Schweiz Demenzkostenstudie 2019: Gesellschaftliche Perspektive. Alzheimer Schweiz. Bern; 2019.
5 Bundesamt für Gesundheit (BAG). 2019. Bestandsaufnahme Swiss Memory Clinics – Nationale Demenzstrategie 2014–2019.
6 Cacciamani F, Houot M, Gagliardi G, Dubois B, Sikkes S, Sánchez-Benavides G, et al. Awareness of Cognitive Decline in Patients With Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2021;13:697234.
7 Bürge M, Bieri G, Brühlmeier M, Colombo F, Demonet JF, Felbecker A, et al. Die Empfehlungen der Swiss Memory Clinics für die Diagnostik der Demenzerkrankungen. Praxis. 2018;107(8):435–51.
8 Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7(3):270–79.
9 Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62.
10 Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7(3):280–92.
11 McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7(3):263–69.
12 Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al.. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.
13 Folstein MF, Folstein SE, McHugh PR. „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
14 American Psychiatric Association, DSM-5 Task Force. (2013). Diagnostic and statistical manual of mental disorders: DSM-5™. 5th ed. American Psychiatric Publishing, Inc; 2013.
15 Schmid NS, Ehrensperger M, Berres M, Beck IR, Monsch AU. The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. Dement Geriatr Cogn Dis Extra. 2014;4(2):322–34.
16 Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3 of the Alzheimer Disease Centers‘ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018;32(1):10–7.
17 Boccardi M, Monsch AU, Ferrari C, Altomare D, Berres M, Bos I, et al.; Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimers Dement. 2022;18(1):29–42.
18 Nutt JG. Higher-level gait disorders: an open frontier. Mov Disord. 2013;28(11):1560–5.
19 Juengling FD, Allenbach G, Bruehlmeier M, Klaeser B, Wissmeyer MP, Garibotto V, et al. Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics. Nuklearmedizin. 2021;60(1):7–9.
20 Felbecker A, Früh S, Unschuld PG, Diener S. Diagnostik. In Felbecker A, immroth V, Tettenborn B, editors. ELSEVIER ESSENTIALS Demenzerkrankungen. ELSEVIER; 2019. pp. 13-42.
21 Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid ẞ (Aẞ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimers Res Ther. 2019;11(1):34.
22 Felbecker A, Loser V, Pot C, Jung HH. Der Demenzursache auf der Spur – genau genau hinschauen lohnt sich! Swiss Med Forum. 2023;23(13):984–985.
23 Palmqvist S., Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL, Hansson O. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034–42.
24 Duering M, Konieczny MJ, Tied S, Baykara E, Tuladhar A, Lyrer P, et al. Neurofilament Light Chain as Serum Marker for Cerebral Small Vessel Disease Burden. J Stroke. 2018;20:228–38.
25 Peters N, van Leijsen E, Tuladhar AM, Barro C, Konieczny MJ, Ewers M, et al. Serum neurofilament light chain is associated with incident lacunes in progressive cerebral small vessel disease. J Stroke. 2020;22:369/76.
26 Egle M, Loubiere L, Maceski A, Kuhle J, Peters N, Markus HS. Neurofilament Light Chain Predicts Future Dementia Risk in Cerebral Small Vessel Disease. J Neurol Neurosurg Psychiatry. 2021;92(6):582–9.
27 Nirmalraj P, Schneider T, Felbecker A. Spatial organization of protein aggregates on red blood cells
https://register.awmf.org/de/leitlinien/detail/038-013 as physical biomarkers of Alzheimer‘s disease pathology. Sci Adv. 2021;7(39):eabj2137.
28 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN) und Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie «Demenzen». 2016.
https://register.awmf.org/de/leitlinien/detail/038-013